Pembrolizumab is an immune checkpoint blocker that blocks the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2, leading to enhanced T-cell activation and immune response against cancer cells. Here, PDCD1 is linked to cancer.